Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
News|Articles|May 10, 2019
EMA Launches Social Media Campaign on Medicines Safety
Author(s)Pharmaceutical Technology Editors
EMA has launched a social media campaign aimed at highlighting how the agency and its network maintain safety and efficacy of medicines available in Europe.
Advertisement
In a May 6, 2019 press release, the European Medicines Agency (EMA) announced the launch of a social media campaign aimed at highlighting how the agency and its network maintain safety and efficacy of medicines available in Europe.
Through a series of info-cards shared via EMA’s LinkedIn and Twitter accounts, the agency describes the added value of European cooperation in keeping medicines safe. The visuals demonstrate how various actions such as pooling resources to monitor and analyse safety information across the region, raising safety standards, and allowing patients to directly report side effects and identify legally operating online pharmacies and retailers, all aid in keeping medicines safe.
As a key priority for EMA, the European Commission, and the network of national authorities that provide the agency with scientific expertise for medicines regulation, the agency encourages everyone to support the campaign through sharing the info-cards on social media themselves.
Source:
Advertisement
Related to this article
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Advertisement
Advertisement